Should I buy or sell Walgreens Boots Alliance stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Walgreens Boots Alliance in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WBA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WBA, but not buy additional shares or sell existing shares. View WBA analyst ratings or view top-rated stocks .

What is Walgreens Boots Alliance's stock price target for 2024?

10 brokerages have issued twelve-month price targets for Walgreens Boots Alliance's stock. Their WBA share price targets range from $21.00 to $45.00. On average, they predict the company's share price to reach $29.36 in the next year. This suggests a possible upside of 45.7% from the stock's current price. View analysts price targets for WBA or view top-rated stocks among Wall Street analysts .

How have WBA shares performed in 2023?

Walgreens Boots Alliance's stock was trading at $37.36 at the start of the year. Since then, WBA stock has decreased by 46.1% and is now trading at $20.15. View the best growth stocks for 2023 here .

When is Walgreens Boots Alliance's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, January 4th 2024. View our WBA earnings forecast .

How were Walgreens Boots Alliance's earnings last quarter?

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) posted its quarterly earnings data on Thursday, October, 12th. The pharmacy operator reported $0.67 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.69 by $0.02. The pharmacy operator earned $35.42 billion during the quarter, compared to analysts' expectations of $34.81 billion. Walgreens Boots Alliance had a positive trailing twelve-month return on equity of 12.31% and a negative net margin of 2.21%. The business's revenue was up 9.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.80 earnings per share. Read the conference call transcript .

How often does Walgreens Boots Alliance pay dividends? What is the dividend yield for Walgreens Boots Alliance?

Walgreens Boots Alliance announced a quarterly dividend on Thursday, October 26th. Shareholders of record on Tuesday, November 14th will be given a dividend of $0.48 per share on Tuesday, December 12th. This represents a $1.92 dividend on an annualized basis and a yield of 9.53%. The ex-dividend date is Monday, November 13th. Read our dividend analysis for WBA .

Is Walgreens Boots Alliance a good dividend stock?

Walgreens Boots Alliance (NASDAQ:WBA) pays an annual dividend of $1.92 per share and currently has a dividend yield of 9.55%. WBA has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Read our dividend analysis for WBA .

What ETFs hold Walgreens Boots Alliance's stock?

ETFs with the largest weight of Walgreens Boots Alliance (NASDAQ:WBA) stock in their portfolio include Invesco Dow Jones Industrial Average Dividend ETF (DJD) , FT Cboe Vest DJIA Dogs 10 Target Income ETF (DOGG) , Invesco S&P Ultra Dividend Revenue ETF (RDIV) , Sound Equity Dividend Income ETF (DIVY) , Sound Equity Income ETF (SDEI) , First Trust Dow 30 Equal Weight ETF (EDOW) , USCF Dividend Income Fund (UDI) and Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) .

What guidance has Walgreens Boots Alliance issued on next quarter's earnings?

Walgreens Boots Alliance updated its FY 2024 earnings guidance on Thursday, October, 12th. The company provided EPS guidance of $3.20-$3.50 for the period, compared to the consensus estimate of $3.41. The company issued revenue guidance of $141.00 billion-$145.00 billion, compared to the consensus revenue estimate of $144.36 billion.

What is Stefano Pessina's approval rating as Walgreens Boots Alliance's CEO?

4,267 employees have rated Walgreens Boots Alliance Chief Executive Officer Stefano Pessina on Glassdoor.com . Stefano Pessina has an approval rating of 32% among the company's employees. This puts Stefano Pessina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Walgreens Boots Alliance own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Walgreens Boots Alliance investors own include AT&T (T) , Intel (INTC) , CVS Health (CVS) , Johnson & Johnson (JNJ) , Walt Disney (DIS) , Cisco Systems (CSCO) , AbbVie (ABBV) , Verizon Communications (VZ) , Pfizer (PFE) and Exxon Mobil (XOM) .

Who are Walgreens Boots Alliance's major shareholders?

Walgreens Boots Alliance's stock is owned by a variety of institutional and retail investors. Top institutional investors include Invesco Ltd. (1.97%), Morgan Stanley (1.46%), Northern Trust Corp (0.89%), Legal & General Group Plc (0.77%), Bank of New York Mellon Corp (0.74%) and Charles Schwab Investment Management Inc. (0.68%). Insiders that own company stock include John Patrick Driscoll , Kevin M Ban , Nancy M Schlichting , Richard P Gates , Rosalind G Brewer and Walgreens Boots Alliance, Inc. View institutional ownership trends .

How do I buy shares of Walgreens Boots Alliance?

Shares of WBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Walgreens Boots Alliance have any subsidiaries?

The following companies are subsidiares of Walgreens Boots Alliance: Alliance Boots Holdings Limited, Alliance Healthcare Deutschland AG, Bond Drug Company of Illinois LLC, Boots Opticians Professional Services Limited, Boots Properties Limited, Boots Property Partnerships, Boots Retail (Ireland) Limited, Boots Retail (Thailand) Limited, Boots UK Limited, Duane Reade, Farmacias Benavides S.A.B. de C.V., Innovation Associates Inc, Liz Earle Beauty, Prime Therapeutics Specialty Pharmacy LLC, Shields Health Solutions, Sinopharm Holding GuoDa Drug Store Co., Superior Acquisitions Limited, Superior Holdings Limited, Superior Luxco 1 S.à r.l., Take Care Health Employer Solutions, The Boots Company PLC, WBA Acquisitions UK Holdco 7 Limited, WBA Acquisitions UK Topco Limited, WBA Financial LLC, WBA International Limited, WBA Investments Inc., WBA Luxembourg 6 S.à r.l., WBA Luxembourg 7 S.à.r.l., WBAD Holdings Limited, Walgreen Arizona Drug Co., Walgreen Co., Walgreen Eastern Co. Inc., Walgreen International S.à r.l., Walgreen Investments Luxembourg S.à r.l., Walgreen Louisiana Co. Inc., Walgreen of Puerto Rico Inc., Walgreens Boots Alliance (Hong Kong) Investments Limited, Walgreens Boots Alliance Holdings LLC, Walgreens Boots Alliance Limited, Walgreens Specialty Pharmacy LLC, and Waltrust Properties Inc.. Read More

Walgreens Boots Alliance Stock Price, News & Analysis (NASDAQ:WBA)

$20.15

+0.17 (+0.85%)

(As of 01:28 PM ET)

Compare

Today's Range: $19.92
▼
$20.47
50-Day Range: $19.98
▼
$24.19
52-Week Range: $19.75
▼
$42.29

Volume: 6.05 million shs
Average Volume: 9.16 million shs
Market Capitalization: $17.41 billion

P/E Ratio: N/A
Dividend Yield: 9.53%
Price Target: $29.36

Walgreens Boots Alliance MarketRank™ Stock Analysis

Analyst Rating: Hold
2.10 Rating Score
Upside/Downside: 43.8% Upside
$29.36 Price Target
Short Interest: Bearish
7.28% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.09
Upright™ Environmental Score
News Sentiment: -0.06
Based on 10 Articles This Week
Insider Trading: Selling Shares
$20,450 Sold Last Quarter
Proj. Earnings Growth: 9.28%
From $3.34 to $3.65 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Retail/Wholesale Sector

25th out of 204 stocks

Drug Stores & Proprietary Stores Industry

2nd out of 4 stocks

4.1

Analyst's Opinion

Consensus Rating
Walgreens Boots Alliance has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on 2 buy ratings, 7 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $29.36, Walgreens Boots Alliance has a forecasted upside of 43.8% from its current price of $20.42.
Amount of Analyst Coverage
Walgreens Boots Alliance has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
7.28% of the float of Walgreens Boots Alliance has been sold short.
Short Interest Ratio / Days to Cover
Walgreens Boots Alliance has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in Walgreens Boots Alliance has recently increased by 13.47%, indicating that investor sentiment is decreasing significantly.

4.2

Dividend Strength

Dividend Leadership
Walgreens Boots Alliance is a leading dividend payer. It pays a dividend yield of 9.55%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Walgreens Boots Alliance has been increasing its dividend for 47 years.
Dividend Sustainability
Based on earnings estimates, Walgreens Boots Alliance will have a dividend payout ratio of 52.60% next year. This indicates that Walgreens Boots Alliance will be able to sustain or increase its dividend.

2.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Walgreens Boots Alliance has received a 9.05% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Physical retail of dental health products at a pharmacy", "Wholesale of pharmaceuticals", and "Physical retail of pharmaceuticals at a pharmacy" products. See details.
Environmental Sustainability
The Environmental Impact score for Walgreens Boots Alliance is -2.09.

1.6

News and Social Media Coverage

News Sentiment
Walgreens Boots Alliance has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Retail/Wholesale companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Walgreens Boots Alliance this week, compared to 15 articles on an average week.
Search Interest
150 people have searched for WBA on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.
MarketBeat Follows
Only 32 people have added Walgreens Boots Alliance to their MarketBeat watchlist in the last 30 days. This is a decrease of -27% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Walgreens Boots Alliance insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,450.00 in company stock.
Percentage Held by Insiders
17.40% of the stock of Walgreens Boots Alliance is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
57.92% of the stock of Walgreens Boots Alliance is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Walgreens Boots Alliance are expected to grow by 9.28% in the coming year, from $3.34 to $3.65 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Walgreens Boots Alliance is -5.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Walgreens Boots Alliance is -5.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Walgreens Boots Alliance has a PEG Ratio of 1.21. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Walgreens Boots Alliance has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Walgreens Boots Alliance Stock (NASDAQ:WBA)

Walgreens Boots Alliance Inc. is a world-renowned healthcare, pharmacy, and retailing company. Founded in 1901 by John Boot and Charles R. Walgreen, the company has grown to become a leader in the industry, operating in nine countries and providing access to healthcare services to millions of people around the world. Walgreens Boots Alliance operates through three main segments: U.S. Retail Pharmacy, International, and U.S. Healthcare.

The U.S. Retail Pharmacy segment includes the Walgreens business, which operates health and wellness services, retail drugstores, specialty and home delivery pharmacy services, and an equity method investment in AmerisourceBergen. Walgreens stores have locations in all 50 U.S. states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, offering access to consumer goods and services, pharmacy, photo department, and health and wellness services. Walgreens also operates online stores like Walgreens.com, Drugstore.com, VisionDirect.com, and Beauty.com.

The International segment consists of pharmacy-led health and beauty retail businesses outside the United States and a pharmaceutical wholesaling and distribution company in Germany. This segment includes the Boots brand, which has a history stretching back over 170 years in the United Kingdom, and stores in Ireland and Thailand with Boots franchise operations in the Middle East and Indonesia. The remainder of the division comprises Farmacias Ahumada (FASA) pharmacies in Chile and Benavides in Mexico. The Pharmaceutical Wholesale Division, including the Alliance Healthcare brand, supplied medicines and other healthcare products to more than 115,000 doctors, health centers, pharmacies, and hospitals annually in eleven countries through 306 distribution centers. AmerisourceBergen purchased most of the Alliance Healthcare wholesale division in June 2021 for $6.275bn in cash.

The U.S. Healthcare segment is a consumer-centric, technology-enabled healthcare business that engages consumers through a personalized, omnichannel experience across the care journey. This segment includes the operation of 334 VillageMD clinics, including 146 co-located clinics, 124 standalone clinics, and 64 affiliate clinics.

Walgreens Boots Alliance produces many brands, including Soltan and Botanics, Boots Pharmaceuticals, and Boots Laboratories, No. 7, that Alliance Boots and Walgreens sought to launch internationally following the first share purchase in 2012. These brands include the famous No. 7 beauty serums, developed in Nottingham, the UVA 5-star suncare protection by Soltan, and the Botanics range, developed in partnership with the Royal Botanic Gardens, Kew. Boots' brand range includes medicines, healthcare products, skincare, and many more. Walgreens also has a self-branded line of products called "Well at Walgreens."

For the fiscal year 2020, Walgreens Boots Alliance reported earnings of US$456 million. The reported revenue was US$139.5 billion, an increase of 2.5% over the previous fiscal cycle. As of 2022, Walgreens Boots Alliance is ranked #18 on the Fortune 500 rankings. The company pays a Quarterly dividend of $0.48, representing an annual dividend yield of 5.08%. Wall Street analysts consider Walgreens stock to be Undervalued.

Walgreens Boots Alliance has 862,503,540 shares outstanding, and its market cap is currently $31.99B. The company’s EPS estimate is $1.12, and its most recent earnings report saw it beat expectations with an EPS of $1.16. Following the earnings report, the stock price went down -6.135%. Among the most significant hedge funds holding Walgreens Boots Alliance’s shares is Antipodes Partners Ltd., which owns shares valued at $58M.

Walgreens Boots Alliance is a global healthcare leader committed to providing high-quality services and products to its customers. The company’s innovative strategies have earned it a reputation as a reliable and reputable partner for healthcare providers and consumers. With its wide array of products and services, Walgreens Boots Alliance is well-positioned to continue growing and meeting the needs of its customers for years to come.

WBA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

WBA Stock News Headlines

November 28, 2023 | marketbeat.com

Teva Pharma is the way to play the re-rise of generic drugs (WBA)

Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth

November 20, 2023 | marketbeat.com

What's open and closed on Thanksgiving this year?

The holiday season is here, which means spending time with family on Thanksgiving and also, for millions of people, hunting for the best deals on Black Friday

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 18, 2023 | marketbeat.com

4 high yields near 52-week lows worth looking at (WBA)

These stocks trading near 52-week lows provide high-yielding values for buy-and-hold investors; most are at or near their bottom and may rebound soon

November 15, 2023 | marketbeat.com

3 value stocks you shouldn't let go of this quarter (WBA)

The market has created the perfect opportunity for you to have your cake and eat it too. These three value stocks will likely be portfolio residents soon

November 6, 2023 | marketbeat.com

MarketBeat ‘Stock of the Week’: Spirit Realty deal rattles REITs (WBA)

A deal between Realty Income and Spirit Realty could create a retail REIT with greater market clout - and boost the sector’s long-term growth prospects.

November 29, 2023 | finance.yahoo.com

Get To Know a CareCentrix Nurse Coach

November 28, 2023 | finance.yahoo.com

Walmart, Target and Walgreens have a second theft problem

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 27, 2023 | finance.yahoo.com

Walgreens Highlights the Need for Clinical Trial Recruitment in Rural Communities

November 24, 2023 | finance.yahoo.com

Boots: one step closer to the block

November 24, 2023 | finance.yahoo.com

Walgreens Unit Boots Transfers $6 Billion Pension Plan, Paving the Way for Future Sale

November 24, 2023 | uk.finance.yahoo.com

Boots owner offloads £4.8bn pension scheme ahead of expected revival of sale process

November 23, 2023 | americanbankingnews.com

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) Given Consensus Rating of "Hold" by Brokerages

November 22, 2023 | realmoney.thestreet.com

Walgreens Boots Alliance price target lowered to $22 from $25 at Evercore ISI

November 21, 2023 | finance.yahoo.com

Looking for a High-Yield Dividend Stock? Avoid Buying Walgreens Boots Alliance.

November 21, 2023 | seekingalpha.com

Walgreens: Management Changes, An Uncertain Future, Weak Momentum Are High Hurdles

November 21, 2023 | seekingalpha.com

Walgreens: Don't Expect An Easy Way Out - Better To Avoid

November 20, 2023 | finance.yahoo.com

Walgreens Boots Alliance (WBA) Stock Dips While Market Gains: Key Facts

November 20, 2023 | seekingalpha.com

Walgreens Boots Alliance: Upgrading To Buy Based On Cost Cuts And Low Bar

November 20, 2023 | seekingalpha.com

Walgreens: This Dog Of The Dow Will Have To Cut Their Dividend To Enable Growth

November 20, 2023 | forbes.com

Walgreens Paves Way To Revive Boots Sale With Pension Deal

November 19, 2023 | finance.yahoo.com

Is This Ultra-High-Yield Dividend Stock a Buy?

November 17, 2023 | benzinga.com

Thinking about buying stock in Palo Alto Networks, Walgreens Boots Alliance, Peraso, Evelo Biosciences, or Safe & Green Development?

November 16, 2023 | finance.yahoo.com

5 Ways Walgreens Supports Those Living With Diabetes

November 16, 2023 | finance.yahoo.com

Don't Bet on Walgreens Boots Alliance Stock's Bounce Just Yet

November 16, 2023 | marketwatch.com

Most Walgreens stores will be closed for Thanksgiving

See More Headlines

Receive WBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Walgreens Boots Alliance and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/12 Dividend: 8/18/2023
Dividend Payable: 9/12/2023
Last Earnings: 10/12/2023
Ex-Dividend for 12/12 Dividend: 11/13/2023
Today: 11/29/2023
Dividend Payable: 12/12/2023
Next Earnings (Estimated): 1/04/2024
Fiscal Year End: 8/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Drug stores & proprietary stores
Sub-Industry: Drug Retail
Sector: Retail/Wholesale
Current Symbol: NASDAQ:WBA
CUSIP: 93142210
CIK: 1618921
Web: www.walgreensbootsalliance.com
Phone: (847) 315-3700
Fax: 847-914-2804
Employees: 331,000
Year Founded: 2014

Price Target and Rating

Average Stock Price Target: $29.36
High Stock Price Target: $45.00
Low Stock Price Target: $21.00
Potential Upside/Downside: +45.5%
Consensus Rating: Hold
Rating Score (0-4): 2.10
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 6.04
P/E Growth: 1.21
Net Income: $-3,080,000,000.00
Net Margins: -2.21%
Pretax Margin: -3.90%
Return on Equity: 12.31%
Return on Assets: 3.54%

Debt

Debt-to-Equity Ratio: 0.29
Current Ratio: 0.63
Quick Ratio: 0.30

Sales & Book Value

Annual Sales: $139.08 billion
Price / Sales: 0.13
Cash Flow: $6.62 per share
Price / Cash Flow: 3.05
Book Value: $32.78 per share
Price / Book: 0.62

Miscellaneous

Outstanding Shares: 863,910,000
Free Float: 713,594,000
Market Cap: $17.43 billion
Optionable: Optionable
Beta: 0.80

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Stefano Pessina (Age 82)
Executive Chairman of the Board
Comp: $111.25k
Ms. Ornella Barra (Age 70)
Chief Operating Officer of International
Comp: $3.11M
Mr. Timothy C. Wentworth (Age 63)
CEO & Director
Mr. Manmohan Mahajan (Age 44)
Senior VP & Interim Global CFO
Mr. Todd D. Heckman (Age 50)
VP, Interim Global Controller & Chief Accounting Officer
Dr. Neal Joseph Sample Ph.D. (Age 48)
Executive VP & Chief Information Officer
Mr. Gerald Gradwell (Age 55)
Senior Vice President of Investor Relations
Ms. Danielle Carim Gray (Age 45)
Executive VP & Global Chief Legal Officer
Ms. Beth A. Leonard
Senior VP & Chief Communications Officer
Ms. Holly May (Age 40)
Executive VP & Global Chief Human Resources Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Walgreens Boots Alliance Stock? WBA Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Walgreens Boots Alliance was last updated on Thursday, November 16, 2023 at 12:00 AM.

Pros

Here are some ways that investors could benefit from investing in Walgreens Boots Alliance, Inc.:

Strong Market Presence: Walgreens Boots Alliance, Inc. has a strong market presence as one of the largest retail pharmacy chains in the world. This provides stability and potential for growth in the healthcare industry.
Diversified Revenue Streams: The company has diversified revenue streams, including retail pharmacy, pharmaceutical wholesale, and retail healthcare services. This diversification helps mitigate risks and provides multiple avenues for revenue generation.
Strategic Partnerships: Walgreens Boots Alliance, Inc. has formed strategic partnerships with various healthcare organizations, such as UnitedHealth Group and LabCorp. These partnerships can lead to collaborative opportunities and increased market reach.
Expansion into Digital Health: The company has been investing in digital health initiatives, including telehealth services and digital prescription management. This positions Walgreens Boots Alliance, Inc. to capitalize on the growing demand for digital healthcare solutions.
Attractive Valuation: Based on recent financial data, Walgreens Boots Alliance, Inc. is trading at an attractive valuation compared to its industry peers. This presents a potential opportunity for investors looking for undervalued stocks.

Cons

Investors should be bearish about investing in Walgreens Boots Alliance, Inc. for these reasons:

Competition from Online Retailers: The company faces intense competition from online retailers, which could impact its retail pharmacy business. The shift towards online shopping in the healthcare industry poses a challenge for Walgreens Boots Alliance, Inc.
Regulatory Risks: The healthcare industry is subject to various regulatory changes and reforms. These regulatory risks can impact the operations and profitability of Walgreens Boots Alliance, Inc.
Declining Prescription Reimbursement Rates: The company's profitability is influenced by prescription reimbursement rates, which have been declining in recent years. This trend could negatively impact the financial performance of Walgreens Boots Alliance, Inc.
Potential Impact of Drug Pricing Policies: Changes in drug pricing policies, such as government regulations or payer negotiations, can affect the profitability of Walgreens Boots Alliance, Inc. and its ability to generate revenue from pharmaceutical sales.
COVID-19 Pandemic: The ongoing COVID-19 pandemic has disrupted the healthcare industry and could have a negative impact on Walgreens Boots Alliance, Inc.'s operations, supply chain, and customer demand.

WBA Stock Analysis - Frequently Asked Questions

Should I buy or sell Walgreens Boots Alliance stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Walgreens Boots Alliance in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WBA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WBA, but not buy additional shares or sell existing shares.
View WBA analyst ratings or view top-rated stocks.
What is Walgreens Boots Alliance's stock price target for 2024?: 10 brokerages have issued twelve-month price targets for Walgreens Boots Alliance's stock. Their WBA share price targets range from $21.00 to $45.00. On average, they predict the company's share price to reach $29.36 in the next year. This suggests a possible upside of 45.7% from the stock's current price.
View analysts price targets for WBA or view top-rated stocks among Wall Street analysts.
How have WBA shares performed in 2023?: Walgreens Boots Alliance's stock was trading at $37.36 at the start of the year. Since then, WBA stock has decreased by 46.1% and is now trading at $20.15.
View the best growth stocks for 2023 here.
When is Walgreens Boots Alliance's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, January 4th 2024.
View our WBA earnings forecast.
How were Walgreens Boots Alliance's earnings last quarter?: Walgreens Boots Alliance, Inc. (NASDAQ:WBA) posted its quarterly earnings data on Thursday, October, 12th. The pharmacy operator reported $0.67 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.69 by $0.02. The pharmacy operator earned $35.42 billion during the quarter, compared to analysts' expectations of $34.81 billion. Walgreens Boots Alliance had a positive trailing twelve-month return on equity of 12.31% and a negative net margin of 2.21%. The business's revenue was up 9.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.80 earnings per share.
Read the conference call transcript.
How often does Walgreens Boots Alliance pay dividends? What is the dividend yield for Walgreens Boots Alliance?: Walgreens Boots Alliance announced a quarterly dividend on Thursday, October 26th. Shareholders of record on Tuesday, November 14th will be given a dividend of $0.48 per share on Tuesday, December 12th. This represents a $1.92 dividend on an annualized basis and a yield of 9.53%. The ex-dividend date is Monday, November 13th.
Read our dividend analysis for WBA.
Is Walgreens Boots Alliance a good dividend stock?: Walgreens Boots Alliance (NASDAQ:WBA) pays an annual dividend of $1.92 per share and currently has a dividend yield of 9.55%. WBA has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for WBA.
What ETFs hold Walgreens Boots Alliance's stock?: ETFs with the largest weight of Walgreens Boots Alliance (NASDAQ:WBA) stock in their portfolio include Invesco Dow Jones Industrial Average Dividend ETF (DJD), FT Cboe Vest DJIA Dogs 10 Target Income ETF (DOGG), Invesco S&P Ultra Dividend Revenue ETF (RDIV), Sound Equity Dividend Income ETF (DIVY), Sound Equity Income ETF (SDEI), First Trust Dow 30 Equal Weight ETF (EDOW), USCF Dividend Income Fund (UDI) and Invesco S&P 500 High Dividend Low Volatility ETF (SPHD).

What guidance has Walgreens Boots Alliance issued on next quarter's earnings?: Walgreens Boots Alliance updated its FY 2024 earnings guidance on Thursday, October, 12th. The company provided EPS guidance of $3.20-$3.50 for the period, compared to the consensus estimate of $3.41. The company issued revenue guidance of $141.00 billion-$145.00 billion, compared to the consensus revenue estimate of $144.36 billion.
What is Stefano Pessina's approval rating as Walgreens Boots Alliance's CEO?: 4,267 employees have rated Walgreens Boots Alliance Chief Executive Officer Stefano Pessina on Glassdoor.com. Stefano Pessina has an approval rating of 32% among the company's employees. This puts Stefano Pessina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Walgreens Boots Alliance own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Walgreens Boots Alliance investors own include AT&T (T), Intel (INTC), CVS Health (CVS), Johnson & Johnson (JNJ), Walt Disney (DIS), Cisco Systems (CSCO), AbbVie (ABBV), Verizon Communications (VZ), Pfizer (PFE) and Exxon Mobil (XOM).
Who are Walgreens Boots Alliance's major shareholders?: Walgreens Boots Alliance's stock is owned by a variety of institutional and retail investors. Top institutional investors include Invesco Ltd. (1.97%), Morgan Stanley (1.46%), Northern Trust Corp (0.89%), Legal & General Group Plc (0.77%), Bank of New York Mellon Corp (0.74%) and Charles Schwab Investment Management Inc. (0.68%). Insiders that own company stock include John Patrick Driscoll, Kevin M Ban, Nancy M Schlichting, Richard P Gates, Rosalind G Brewer and Walgreens Boots Alliance, Inc.
View institutional ownership trends.
How do I buy shares of Walgreens Boots Alliance?: Shares of WBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does Walgreens Boots Alliance have any subsidiaries?: The following companies are subsidiares of Walgreens Boots Alliance: Alliance Boots Holdings Limited, Alliance Healthcare Deutschland AG, Bond Drug Company of Illinois LLC, Boots Opticians Professional Services Limited, Boots Properties Limited, Boots Property Partnerships, Boots Retail (Ireland) Limited, Boots Retail (Thailand) Limited, Boots UK Limited, Duane Reade, Farmacias Benavides S.A.B. de C.V., Innovation Associates Inc, Liz Earle Beauty, Prime Therapeutics Specialty Pharmacy LLC, Shields Health Solutions, Sinopharm Holding GuoDa Drug Store Co., Superior Acquisitions Limited, Superior Holdings Limited, Superior Luxco 1 S.à r.l., Take Care Health Employer Solutions, The Boots Company PLC, WBA Acquisitions UK Holdco 7 Limited, WBA Acquisitions UK Topco Limited, WBA Financial LLC, WBA International Limited, WBA Investments Inc., WBA Luxembourg 6 S.à r.l., WBA Luxembourg 7 S.à.r.l., WBAD Holdings Limited, Walgreen Arizona Drug Co., Walgreen Co., Walgreen Eastern Co. Inc., Walgreen International S.à r.l., Walgreen Investments Luxembourg S.à r.l., Walgreen Louisiana Co. Inc., Walgreen of Puerto Rico Inc., Walgreens Boots Alliance (Hong Kong) Investments Limited, Walgreens Boots Alliance Holdings LLC, Walgreens Boots Alliance Limited, Walgreens Specialty Pharmacy LLC, and Waltrust Properties Inc..
Read More

This page (NASDAQ:WBA) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial